morphine sulfate injection, USP 50 MG/ML VIAL Highlights

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use MORPHINE SULFATE INJECTION safely and effectively. See full prescribing information for MORPHINE SULFATE INJECTION.

MORPHINE SULFATE injection, for intravenous use, CII

Initial U.S. Approval: 1941

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF MORPHINE SULFATE INJECTION

See full prescribing information for complete boxed warning.

Morphine Sulfate Injection exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient’s risk before prescribing and reassess regularly for these behaviors and conditions. (5.1)
Serious, life-threatening, or fatal respiratory depression may occur with use of Morphine Sulfate Injection, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of ‎Morphine Sulfate Injection are essential. (5.2)
Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate. (5.3, 7)
If opioid use is required for an extended period of time in a pregnant woman, advise the patient of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. Ensure that management by neonatology expert will be available at delivery. (5.4)

RECENT MAJOR CHANGES

Boxed Warning

12/2023

Indications and Usage (1)

12/2023

Dosage and Administration (2.1, 2.2, 2.3)

12/2023

Warnings and Precautions (5.6)

12/2023

INDICATIONS AND USAGE

Morphine Sulfate Injection is an opioid agonist indicated in adult and pediatric patients for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. (1)

Limitations of Use (1)

Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration (5.1), reserve Morphine Sulfate Injection for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products):

Have not been tolerated or are not expected to be tolerated
Have not provided adequate analgesia or are not expected to provide adequate analgesia

Morphine Sulfate Injection should not be used for an extended period of time ‎unless the pain remains severe enough to require an opioid analgesic and ‎for which alternative treatment options continue to be inadequate.‎

DOSAGE AND ADMINISTRATION

Morphine Sulfate Injection should be prescribed only by healthcare ‎professionals who are knowledgeable about the use of opioids and how ‎to ‎mitigate the associated risks. (2.1)‎
Use the lowest effective dosage for the shortest duration of time consistent with individual patient treatment goals. Reserve titration to higher ‎doses of Morphine Sulfate Injection for patients in whom lower doses are ‎‎insufficiently effective and in whom the expected benefits of using a ‎higher dose opioid clearly outweigh the substantial risks. (2.1, 5)‎
Many acute pain conditions (e.g., the pain that occurs with a number ‎of surgical procedures or acute musculoskeletal injuries) require no ‎more ‎than a few days of an opioid analgesic. Clinical guidelines on ‎opioid prescribing for some acute pain conditions are available. (2.1)‎
Initiate the dosing regimen for each patient ‎individually, taking into account the patient’s underlying cause and ‎severity of ‎pain, prior analgesic treatment and response, and risk ‎factors for addiction, abuse, and misuse. (2.1, 5.1)‎
Respiratory depression can occur at any time during opioid therapy, ‎especially when initiating and following dosage increases with ‎Morphine ‎Sulfate Injection. Consider this risk when selecting an initial ‎dose and when making dose adjustments. (2.1, 5.2)‎
Do not inject directly. Morphine Sulfate Injection is intended for continuous intravenous infusion only, after dilution in large volume parenteral solutions. (2.1, 2.5)
Initial and maintenance dosage in adults: See full prescribing information for recommended dosages in adult patients. (2.2, 2.3)
Initial and maintenance dosage in pediatric patients: See full prescribing information for recommended dosage in pediatric patients. (2.2, 2.3)
Do not abruptly discontinue Morphine Sulfate Injection in a physically‑dependent patient. (2.4)
See full prescribing information for preparation and storage instructions. (2.5)

DOSAGE FORMS AND STRENGTHS

Morphine Sulfate Injection, USP is available in 1,000 mg/20 mL (50 mg/mL) and 2,500 mg/50 mL (50 mg/mL) single-dose flip top vials. (3)

CONTRAINDICATIONS

Significant respiratory depression. (4)
Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment. (4)
Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days. (4)
Known or suspected gastrointestinal obstruction, including paralytic ileus. (4)
Hypersensitivity to morphine. (4)

WARNINGS AND PRECAUTIONS

Cardiovascular Instability: High doses are excitatory. Have naloxone injection and resuscitative equipment immediately available. (5.5)
Opioid-Induced Hyperalgesia and Allodynia: Opioid-Induced ‎Hyperalgesia (OIH) occurs when an opioid analgesic paradoxically ‎causes an increase in pain, or an increase in sensitivity to pain. If OIH is suspected, carefully consider ‎appropriately decreasing the dose of the current opioid analgesic or ‎opioid rotation. ‎‎(5.6)‎
Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients: Monitor closely, particularly during initiation and titration. (5.7)
Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid. (5.9)
Severe Hypotension: Monitor during dosage initiation and titration. Avoid use of Morphine Sulfate Injection in patients with circulatory shock. (5.10)
Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness: Monitor for sedation and respiratory depression. Avoid use of Morphine Sulfate Injection in patients with impaired consciousness or coma. (5.11)

ADVERSE REACTIONS

The most serious adverse reactions encountered are respiratory depression, apnea, circulatory depression, respiratory arrest, shock, and cardiac arrest. Other common frequently observed adverse reactions include: sedation, lightheadedness, dizziness, nausea, vomiting, constipation, and diaphoresis. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc. at 1-800-441-4100, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. Discontinue Morphine Sulfate Injection if serotonin syndrome is suspected. (7)
Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics: Avoid use with Morphine Sulfate Injection because they may reduce analgesic effect of Morphine Sulfate Injection or precipitate withdrawal symptoms. (7)

USE IN SPECIFIC POPULATIONS

Pregnancy: May cause fetal harm. (8.1)
Geriatric Patients: Use caution during dose selection, starting at the low ‎end of the dosing range while carefully monitoring for side effects. ‎‎(8.5)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 12/2023

Find morphine sulfate injection, USP 50 MG/ML VIAL medical information:

Find morphine sulfate injection, USP 50 MG/ML VIAL medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

morphine sulfate injection, USP 50 MG/ML VIAL Quick Finder

Prescribing Information
Download Prescribing Information

Health Professional Information

Highlights

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use MORPHINE SULFATE INJECTION safely and effectively. See full prescribing information for MORPHINE SULFATE INJECTION.

MORPHINE SULFATE injection, for intravenous use, CII

Initial U.S. Approval: 1941

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF MORPHINE SULFATE INJECTION

See full prescribing information for complete boxed warning.

Morphine Sulfate Injection exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient’s risk before prescribing and reassess regularly for these behaviors and conditions. (5.1)
Serious, life-threatening, or fatal respiratory depression may occur with use of Morphine Sulfate Injection, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of ‎Morphine Sulfate Injection are essential. (5.2)
Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate. (5.3, 7)
If opioid use is required for an extended period of time in a pregnant woman, advise the patient of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. Ensure that management by neonatology expert will be available at delivery. (5.4)

RECENT MAJOR CHANGES

Boxed Warning

12/2023

Indications and Usage (1)

12/2023

Dosage and Administration (2.1, 2.2, 2.3)

12/2023

Warnings and Precautions (5.6)

12/2023

INDICATIONS AND USAGE

Morphine Sulfate Injection is an opioid agonist indicated in adult and pediatric patients for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. (1)

Limitations of Use (1)

Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration (5.1), reserve Morphine Sulfate Injection for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products):

Have not been tolerated or are not expected to be tolerated
Have not provided adequate analgesia or are not expected to provide adequate analgesia

Morphine Sulfate Injection should not be used for an extended period of time ‎unless the pain remains severe enough to require an opioid analgesic and ‎for which alternative treatment options continue to be inadequate.‎

DOSAGE AND ADMINISTRATION

Morphine Sulfate Injection should be prescribed only by healthcare ‎professionals who are knowledgeable about the use of opioids and how ‎to ‎mitigate the associated risks. (2.1)‎
Use the lowest effective dosage for the shortest duration of time consistent with individual patient treatment goals. Reserve titration to higher ‎doses of Morphine Sulfate Injection for patients in whom lower doses are ‎‎insufficiently effective and in whom the expected benefits of using a ‎higher dose opioid clearly outweigh the substantial risks. (2.1, 5)‎
Many acute pain conditions (e.g., the pain that occurs with a number ‎of surgical procedures or acute musculoskeletal injuries) require no ‎more ‎than a few days of an opioid analgesic. Clinical guidelines on ‎opioid prescribing for some acute pain conditions are available. (2.1)‎
Initiate the dosing regimen for each patient ‎individually, taking into account the patient’s underlying cause and ‎severity of ‎pain, prior analgesic treatment and response, and risk ‎factors for addiction, abuse, and misuse. (2.1, 5.1)‎
Respiratory depression can occur at any time during opioid therapy, ‎especially when initiating and following dosage increases with ‎Morphine ‎Sulfate Injection. Consider this risk when selecting an initial ‎dose and when making dose adjustments. (2.1, 5.2)‎
Do not inject directly. Morphine Sulfate Injection is intended for continuous intravenous infusion only, after dilution in large volume parenteral solutions. (2.1, 2.5)
Initial and maintenance dosage in adults: See full prescribing information for recommended dosages in adult patients. (2.2, 2.3)
Initial and maintenance dosage in pediatric patients: See full prescribing information for recommended dosage in pediatric patients. (2.2, 2.3)
Do not abruptly discontinue Morphine Sulfate Injection in a physically‑dependent patient. (2.4)
See full prescribing information for preparation and storage instructions. (2.5)

DOSAGE FORMS AND STRENGTHS

Morphine Sulfate Injection, USP is available in 1,000 mg/20 mL (50 mg/mL) and 2,500 mg/50 mL (50 mg/mL) single-dose flip top vials. (3)

CONTRAINDICATIONS

Significant respiratory depression. (4)
Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment. (4)
Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days. (4)
Known or suspected gastrointestinal obstruction, including paralytic ileus. (4)
Hypersensitivity to morphine. (4)

WARNINGS AND PRECAUTIONS

Cardiovascular Instability: High doses are excitatory. Have naloxone injection and resuscitative equipment immediately available. (5.5)
Opioid-Induced Hyperalgesia and Allodynia: Opioid-Induced ‎Hyperalgesia (OIH) occurs when an opioid analgesic paradoxically ‎causes an increase in pain, or an increase in sensitivity to pain. If OIH is suspected, carefully consider ‎appropriately decreasing the dose of the current opioid analgesic or ‎opioid rotation. ‎‎(5.6)‎
Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients: Monitor closely, particularly during initiation and titration. (5.7)
Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid. (5.9)
Severe Hypotension: Monitor during dosage initiation and titration. Avoid use of Morphine Sulfate Injection in patients with circulatory shock. (5.10)
Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness: Monitor for sedation and respiratory depression. Avoid use of Morphine Sulfate Injection in patients with impaired consciousness or coma. (5.11)

ADVERSE REACTIONS

The most serious adverse reactions encountered are respiratory depression, apnea, circulatory depression, respiratory arrest, shock, and cardiac arrest. Other common frequently observed adverse reactions include: sedation, lightheadedness, dizziness, nausea, vomiting, constipation, and diaphoresis. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc. at 1-800-441-4100, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. Discontinue Morphine Sulfate Injection if serotonin syndrome is suspected. (7)
Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics: Avoid use with Morphine Sulfate Injection because they may reduce analgesic effect of Morphine Sulfate Injection or precipitate withdrawal symptoms. (7)

USE IN SPECIFIC POPULATIONS

Pregnancy: May cause fetal harm. (8.1)
Geriatric Patients: Use caution during dose selection, starting at the low ‎end of the dosing range while carefully monitoring for side effects. ‎‎(8.5)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 12/2023

Medication Guide

Health Professional Information

{{section_name_patient}}

{{section_body_html_patient}}

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.